Drug intelligence / Profile preview

butropium

Development stage: Unknown
Lead developer: Eisai
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Butropium is a quaternary ammonium antimuscarinic agent with peripheral effects similar to those of atropine. It is primarily indicated for the treatment of pain caused by gastrointestinal inflammation and ulcers, as well as diseases of the gallbladder. Butropium acts by blocking muscarinic acetylcholine receptors in the smooth muscle of the gastrointestinal tract, thereby reducing spasms and associated pain. It is classified under belladonna alkaloids, semisynthetic, quaternary ammonium compounds (ATC code A03BB). The drug is mainly available in Japan under brand names such as Coliopan[8].

Brand names: Coliopan
Other names: butropium bromide

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on butropium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on butropium.

Explore the full profile